Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapyrefractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses.
INTRODUCTION
A human cluster of differentiation antigen (CD) 22 is a B-lymphoid lineage-specific marker expressed on both normal and malignant B cells. Because treatment and cure for many CD22-expressing hematologic malignancies continue to be an unmet need, recombinantly engineered monoclonal antibodies against CD22 hold promise as therapeutic agents. 1, 2 Moxetumomab pasudotox (CAT-8015 or HA22, Moxetumomab) is an affinity-optimized second-generation recombinant immunotoxin consisting of an F v fragment of the mouse anti-hCD22 monoclonal antibody (RFB4) conjugated with a truncated form of Pseudomonas exotoxin A, PE38. 3 Since CD22 is expressed in a lineage-restricted fashion along the B-cell developmental cascade, moxetumomab is being evaluated for treatment against a number of Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukemia; PDX, patient-derived xenograft B-cell malignancies, including B-cell precursor acute lymphoblastic leukemia (BCP-ALL), where approximately 90% of patient blasts are CD22 positive. 4 In hairy cell leukemia, a comparatively more differentiated CD22-expressing malignancy than BCP-ALL, treatments including moxetumomab achieved excellent results. 5 Considerable intrapatient variability in moxetumumab-induced cytotoxicity was observed in a study of 35 primary patient samples, suggesting that variables in underlying BCP-ALL biology might be impacting the response. 6 In a phase I trial of 23 children with BCP-ALL, the clinical burden was only transiently reduced when anti-CD22 immunotoxin was given as a single agent, and there was no obvious influence of CD22 density on clinical activity. 7 To investigate the best potential setting for the inclusion of moxetumomab into clinical practice, we utilized BCP-ALL cell lines and primary patient samples to assess the effects of binding and internalization on ex vivo killing activity. Although we found conditions for which moxetumomab effectively killed BCP-ALL cells ex vivo, it did not impact survival in our patient-derived xenograft (PDX) models. 
RESULTS
Moxetumomab was originally developed using the disulfide-stabilized
Fv region from the mouse monoclonal antibody RFB4 and selected for its high-specificity binding to human CD22. 3 For these studies, moxetumomab was produced at MedImmune (Gaithersburg, MD, USA) using good clinical practice manufacturing techniques. 8 Table 1 .
Two cell lines and five patient blasts expressed common BCP-ALL features, including varying levels of CD22 (Table 1 and Supplementary   Table S1 ). Live cells from both cell lines, as well as patient 280-13, bound significant amounts of fluorescently labeled moxetumomab (moxetumomab-AF488) in a time-dependent manner (blue bars, Table S1 ).
We also used an acid-stripping protocol to examine the accumula- (6,485-54,878, in six cell lines) in comparison with patient samples (713-9,380, median 4,546 receptors/cell), as described in an anti-CD22 immunotoxin phase I clinical trial of 23 subjects having refractory/progressive BCP-ALL. 6 Despite apparent binding and internalization, we did not appreciate a significant benefit in our PDX models, similar to the responses observed in early-phase clinical trials. 7 We confirm here that CD22 expression level is most critical for the early steps of moxetumomab binding and internalization. In addition to CD22 internalization and turnover rates, multiple intracellular trafficking steps are necessary to result in cleavage and production of active toxin. These cellular biologic factors influencing moxetumomab resistance are particularly difficult to measure in an in vivo setting.
Other factors, including leukemia doubling time, additional gene mutations, immune response, and influence from the local microenvironment, likely contribute to reduced response to moxetumomab in PDX models. While a phase I trial for relapsed/refractory hairy cell leukemia moxetumomab achieved an overall response rate of 86%, and a complete remission in 46% of patients, 5 additional work in BCP-ALL may be of questionable significance. Both patients from whom we developed our PDX models remain in first complete remission, without the use of any targeted therapies. However, our modest PDX sample size prevents us from reaching definitive conclusions about which patient subsets might still benefit from such therapy. Further studies with a larger number of patient samples, representing a broader range of cytogenetic alternations and risk groups, will be required for definitive conclusions with respect to the therapeutic promise of moxetumomab.
